ABSTRACT
Objective The TLR4 signaling pathway may be involved in the development and progression of hepatocarcinoma . This study aimed to investigate the effect of inhibiting the TLR 4 signaling pathway on the orthotopic implanted liver tumor (OILT) in mice. Methods A TLR4-silencing siRNA lentiviral vector was constructed and transfected into mouse hepatoma H 22 cells.Mouse hepatoma H22 cells were divided into groups A (blank control), B (empty vector) and C (siRNA lentiviral vector), those in group A left untreated and those in groups B and C infected with an empty vector and the TLR 4-silencing siRNA lentiviral vector , respectively. The volumes of the OILTs in different groups measured and the expressions of TLR 4, MyD88, NF-κB and TRAM in the tumor cells de-termined by immunohistochemistry and Western blot . Results The OILT volume was significantly reduced in group C than in A and B ([568.3±90.3] vs [1303.0±194.1] and [1385.0±137.0] mm3 , P<0.05), and so were the expressions of TLR4, MyD88, NF-κB and TRAM in the tumor cells (P<0.05). Conclusion Down-regula-ting the TLR4 signaling pathway can suppress the growth of the ortho -topic implanted liver tumor in mice, which may be associated with the activation of NF-κB by the MyD88-dependent signaling pathway and that of TRAM by the MyD88-independent signaling pathway .
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the clinical efficacy of capecitabine combined with transcatheter arterial chemoembolization (TACE) for advanced liver cancer.</p><p><b>METHODS</b>Forty-nine patients with liver cancer were retrospectively divided into two groups: Treatment group, on the basis of TACE, 23 patients received oral capecitabine at 2500 mg/m(2), twice-daily for 14 days followed by 7-day rest period and repeated in every three week intervals for more than two cycles. Control group, 26 patients received TACE only at 2-month intervals for at least two cycles.</p><p><b>RESULTS</b>In capecitabine and TACE group: there were 1 CR, 14 PR, 5 SD and 3 PD; the overall response rate was 65.2%; the AFP and tumor reduction rates were 68.8% and 73.9%; the median survival time was 11.9 months. In the TACE only group: there were 0 CR, 7 PR, 12 SD and 7 PD; the overall response rate was 26.9%; the AFP and tumor reduction rates were 31.6 % and 30.8%; the median survival time was 8.3 months. The most common side-effects of capecitabine were hand-foot syndrome and diarrhea.</p><p><b>CONCLUSION</b>Capecitabine combined with TACE is safe and effective for advanced liver cancer.</p>